Investigating how metabolic changes and FGF21 signaling affect kidney health in polycystic kidney disease.
Metabolic reprogramming and FGF21 signaling in kidney health and polycystic kidney diseases
This study is looking at how a special diet that helps your body burn fat might improve kidney health for people with autosomal dominant polycystic kidney disease (ADPKD) and whether it can slow down the disease's progress.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10861027 on NIH RePORTER |
What this research studies
This research focuses on understanding how metabolic reprogramming and the signaling molecule FGF21 can influence kidney health, particularly in patients with autosomal dominant polycystic kidney disease (ADPKD). The study aims to explore the effects of enhancing fatty acid oxidation and the potential benefits of a ketogenic diet on delaying the progression of kidney disease. By examining the molecular mechanisms involved, the research seeks to provide insights into how dietary interventions can be effectively applied in clinical settings to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with autosomal dominant polycystic kidney disease (ADPKD).
Not a fit: Patients with other forms of kidney disease or those without a diagnosis of ADPKD may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new dietary strategies that help slow the progression of kidney disease in patients with ADPKD.
How similar studies have performed: Previous studies have shown promising results with dietary interventions in animal models of PKD, indicating potential for success in human applications.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Dai, Dao-Fu — Johns Hopkins University
- Study coordinator: Dai, Dao-Fu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.